Brokers Offer Predictions for RADX FY2026 Earnings

Radiopharm Theranostics Limited – Sponsored ADR (NASDAQ:RADX) – Stock analysts at Brookline Capital Markets dropped their FY2026 earnings per share estimates for shares of Radiopharm Theranostics in a research note issued on Tuesday, July 28th. Brookline Capital Markets analyst K. Dolliver now forecasts that the company will post earnings of ($3.98) per share for the year, down from their previous estimate of ($2.30). The consensus estimate for Radiopharm Theranostics’ current full-year earnings is ($1.80) per share. Brookline Capital Markets also issued estimates for Radiopharm Theranostics’ FY2027 earnings at ($3.23) EPS.

A number of other equities analysts have also commented on the company. Weiss Ratings reaffirmed a “sell (e+)” rating on shares of Radiopharm Theranostics in a research note on Friday, July 17th. HC Wainwright started coverage on shares of Radiopharm Theranostics in a research note on Thursday, June 4th. They issued a “buy” rating and a $6.00 price objective on the stock. Two analysts have rated the stock with a Buy rating and one has given a Sell rating to the company’s stock. Based on data from MarketBeat.com, the company has a consensus rating of “Hold” and a consensus target price of $11.00.

Radiopharm Theranostics Trading Down 4.8%

NASDAQ RADX opened at $3.15 on Thursday. The business’s 50-day moving average price is $4.30 and its two-hundred day moving average price is $4.58. Radiopharm Theranostics has a 12 month low of $2.73 and a 12 month high of $16.25.

Institutional Investors Weigh In On Radiopharm Theranostics

Large investors have recently bought and sold shares of the stock. Hsbc Holdings PLC acquired a new position in shares of Radiopharm Theranostics during the fourth quarter valued at about $1,007,000. Virtu Financial LLC acquired a new position in Radiopharm Theranostics during the 4th quarter worth approximately $76,000. Jane Street Group LLC bought a new position in Radiopharm Theranostics in the fourth quarter worth approximately $76,000. Finally, Marex Group plc acquired a new stake in Radiopharm Theranostics in the fourth quarter valued at approximately $54,000.

Radiopharm Theranostics Company Profile

Radiopharm Theranostics, Inc is a clinical-stage biopharmaceutical company focused on the development and commercialization of radiopharmaceutical products for both diagnostic imaging and targeted radiotherapeutic applications. By harnessing the unique properties of radioisotopes, the company aims to improve the precision of disease detection and deliver therapeutic payloads directly to diseased tissues, particularly in oncology.

The company’s research and development efforts are concentrated on a pipeline of radioligand therapies and companion diagnostic agents designed to address a variety of tumor types.